<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is the second most common cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>death</z:hpo> in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies showed that interleukin-8 (IL-8) and its receptors (CXCR1 and CXCR2) are significantly upregulated in both the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and its microenvironment, and act as key regulators of proliferation, <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Our previous study showed that IL-8 overexpression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells triggers the upregulation of the CXCR2-mediated proliferative pathway </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this study was to investigate whether the CXCR2 <z:chebi fb="68" ids="48706">antagonist</z:chebi>, SCH-527123, inhibits <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> proliferation and if it can sensitize <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> both in vitro and in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>SCH-527123 showed concentration-dependent antiproliferative effects in HCT116, Caco2, and their respective IL-8-overexpressing variants <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, SCH-527123 was able to suppress CXCR2-mediated signal transduction as shown through decreased phosphorylation of the NF-ÎºB/<z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK)/AKT pathway </plain></SENT>
<SENT sid="6" pm="."><plain>These findings corresponded with decreased cell migration and invasion, while <z:mp ids='MP_0006042'>increased apoptosis</z:mp> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines </plain></SENT>
<SENT sid="7" pm="."><plain>In vivo results verified that SCH-527123 treatment decreased <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and microvessel density when compared with vehicle-treated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Importantly, these preclinical studies showed that the combination of SCH-527123 and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> resulted in a greater decrease in cell proliferation, <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> that was superior to single-agent treatment </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, these findings suggest that targeting CXCR2 may block <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> proliferation, migration, invasion, and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, CXCR2 blockade may further sensitize <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> treatment </plain></SENT>
</text></document>